The Prostate Cancer market was impacted by nmCRPC1, mCSPC2 and mCRPC3 data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for ERLEADA® (apalutamide), XTANDI® (enzalutamide), LYNPARZA® (olaparib), darolutamide, LY3023414 and 177Lu-PSMA-617.
Companies presenting data included: AstraZeneca, Bayer, Eli Lilly, Janssen, Novartis, Pfizer.
Get immediate access to this 62-slide report so you can make better decisions today and prepare for tomorrow.
Prostate Cancer Report ASCO 2019
1. Non-metastatic Castration-resistant Prostate Cancer
2. Metastatic Castration-Sensitive Prostate Cancer
3. Metastatic Castration-resistant Prostate Cancer